{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-007980","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.492283+00:00","generated_at":"2026-05-26T06:00:17.943736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Azitra reports FY2024 net loss of $9.0M; cash $4.6M; trial updates for ATR-12 and ATR-04","bullets":["Net loss $9.0M vs $11.3M in FY2023; R&D expenses $4.7M, G&A $6.3M.","Cash $4.6M at Dec 31, 2024; additional $2.2M raised in Jan/Feb 2025.","Phase 1b trial of ATR-12 in Netherton syndrome ongoing; initial safety data expected H1 2025, topline by year-end.","FDA cleared IND and granted Fast Track for ATR-04 for EGFRi rash; multicenter Phase 1/2 to start H1 2025.","Closed $10M and $5M public offerings in 2024; IP portfolio strengthened."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-007980","json":"https://secwatch.observer/filing/0001493152-25-007980.json","markdown":"https://secwatch.observer/filing/0001493152-25-007980.md","text":"https://secwatch.observer/filing/0001493152-25-007980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/0001493152-25-007980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:00:17.943736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}